secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001437749-25-037910
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia advances CardiAMP Cell Therapy to formal PMDA consultation for HFrEF in Japan
--------------------------------------------------------------------------------

- Completed third preliminary clinical consultation with Japan's PMDA for CardiAMP Cell Therapy (HFrEF).
- PMDA will allow BioCardia to proceed to formal clinical consultation; potential path to regulatory filing.
- Data from three completed Phase I-III trials show improved survival, reduced MACE, and better heart function vs control.
- CEO Peter Altman notes therapy offers a new mechanism of microvascular repair for ischemic HFrEF patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925037910/0001437749-25-037910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925037910/bcda20251216_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer